Search results for " Biological Markers"

showing 10 items of 19 documents

Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome

2014

ObjectiveOn the basis of the known diabetes risk in polycystic ovary syndrome (PCOS), recent guidelines of the Endocrine Society recommend the use of an oral glucose tolerance test (OGTT) to screen for impaired glucose tolerance (IGT) and type 2 diabetes (T2DM) in all women with PCOS. However, given the high prevalence of PCOS, OGTT would have a high cost–benefit ratio. In this study, we identified, through a receiver operating characteristic analysis, simple predictive markers of the composite endpoint (impaired fasting glucose (IFG) or IGT or IFG+IGT or T2DM) in women with PCOS according to the Rotterdam criteria.DesignWe conducted a cross-sectional study of 241 women with PCOS in a unive…

AdultBlood Glucosemedicine.medical_specialtyDiabetes riskWaistendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismType 2 diabetesIntra-Abdominal FatSettore MED/13 - EndocrinologiaImpaired glucose toleranceYoung AdultInsulin resistanceEndocrinologyAdiposity; Adolescent; Adult; Biological Markers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Humans; Intra-Abdominal Fat; Polycystic Ovary Syndrome; Risk Factors; Young Adult; Endocrinology; Endocrinology Diabetes and Metabolism; Medicine (all)Risk FactorsInternal medicineDiabetes mellitusmedicineHumansAdiposityCross-Sectional Studiebusiness.industryRisk FactorMedicine (all)nutritional and metabolic diseasesGeneral MedicineImpaired fasting glucosemedicine.diseasePolycystic ovaryCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2Biological MarkerFemalebusinessBiomarkersHumanPolycystic Ovary Syndrome
researchProduct

Non-specific bronchial hyper-responsiveness in children with allergic rhinitis: relationship with the atopic status

2003

An increased prevalence of bronchial hyper-responsiveness (BHR) has been demonstrated in children from a general population, and in non-asthmatic adults with allergic rhinitis. Thus, also children with allergic rhinitis are expected to be at higher risk of BHR. We evaluated the prevalence of BHR in a sample of non-asthmatic children with allergic rhinitis by means of the methacholine (Mch) bronchial challenge, and by monitorizing the airway patency using the daily peak expiratory flow variability (PEFv). Fifty-one children (ranged 6-15 years of age) with allergic rhinitis, ascertained by skin prick test to inhalant allergens, underwent a 14-day peak expiratory flow monitoring, and a Mch bro…

Cross-Sectional StudieHypersensitivity ImmediateMaleRhinitis Allergic PerennialAdolescentRespiratory Function Tests; Peak Expiratory Flow Rate; Airway Resistance; Vital Capacity; Bronchial Provocation Tests; Humans; Predictive Value of Tests; Child; Forced Expiratory Volume; Child Welfare; Cross-Sectional Studies; Rhinitis Allergic Perennial; Immunoglobulin E; Hypersensitivity Immediate; Bronchial Hyperreactivity; Statistics as Topic; Adolescent; Male; Biological Markers; Female; PrevalenceAirway ResistanceVital CapacityStatistics as TopicChild WelfarePeak Expiratory Flow RatePredictive Value of TestImmunoglobulin EBronchial Provocation TestForced Expiratory VolumeBiological MarkerPrevalenceFemaleBronchial HyperreactivityChildRespiratory Function TestHuman
researchProduct

Missense mutations in the fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis

1997

AbstractProgrammed cell death (or apoptosis) is a physiological process essential to the normal development and homeostatic maintenance of the immune system. The Fas/Apo-1 receptor plays a crucial role in the regulation of apoptosis, as demonstrated by lymphoproliferation in MRL-lpr/lpr mice and by the recently described autoimmune lymphoproliferative syndrome (ALPS) in humans, both of which are due to mutations in the Fas gene. We describe a novel family with ALPS in which three affected siblings carry two distinct missense mutations on both the Fas gene alleles and show lack of Fas-induced apoptosis. The children share common clinical features including splenomegaly and lymphadenopathy, b…

Antigens Differentiation T-LymphocyteMaleAdolescentT-LymphocytesCD3ImmunologyLymphoproliferative disordersBiologyLymphocyte ActivationAutoimmune DiseaseBiochemistryFas ligandImmunophenotypingImmune systemPedigree; Antigens Differentiation T-Lymphocyte; Solubility; Apoptosis; Autoimmune Diseases; Humans; Antigens CD95; Child; Lymphocytes; Child Preschool; Lymphocyte Activation; Syndrome; Lymphoproliferative Disorders; Adolescent; Mutation; Immunophenotyping; Male; Biological Markers; T-LymphocytesmedicineChildAutoimmune diseaseApoptosiSyndromeCell BiologyHematologymedicine.diseaseFas receptorPedigreeAntigens CD95SolubilityApoptosisChild PreschoolLymphoproliferative DisorderAutoimmune lymphoproliferative syndromeMutationBiological MarkerImmunologybiology.proteinLymphocyteHuman
researchProduct

Eligibility for treatment with omalizumab in Italy and Germany.

2013

Summary Omalizumab is an add-on therapy for patients with uncontrolled severe allergic asthma. In Europe, patients must fulfil a number of additional criteria to become eligible for omalizumab therapy, creating a challenge for epidemiology studies to quantify the potential patient pool. Thus, and in the absence of robust data, the number of omalizumab-eligible patients has remained unclear. To assess eligible patient numbers, a chart-audit design approach was employed to measure epidemiology variables based on patient-level data. 770 patient charts were reviewed in designated towns in Germany and Italy, in collaboration with >200 primary care physicians (PCPs) and respiratory specialists (R…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPediatricsReferralEpidemiologySevere asthmaAllergic asthmaEligibility DeterminationOmalizumabPrimary careOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness IndexAntibodiesSampling StudiesDose-Response RelationshipProduct LabelGermanyEpidemiologyMonoclonalmedicinePrevalenceHumansNational levelAnti-Asthmatic AgentsHumanizedAnti-immunoglobulin EEligibilityDose-Response Relationship Drugbusiness.industryPatient SelectionAllergic asthmaImmunoglobulin EAsthmaAntibodies Anti-IdiotypicAnti-IdiotypicTreatment OutcomeItalyQuality of LifeBiological MarkersDrugbusinessBiomarkersmedicine.drugAllergic asthma; Anti-immunoglobulin E; Eligibility; Epidemiology; Anti-Asthmatic Agents; Antibodies Anti-Idiotypic; Antibodies Monoclonal Humanized; Asthma; Biological Markers; Dose-Response Relationship Drug; Eligibility Determination; Germany; Humans; Immunoglobulin E; Italy; Patient Selection; Prevalence; Quality of Life; Sampling Studies; Severity of Illness Index; Treatment OutcomeRespiratory medicine
researchProduct

Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.

2012

International audience; PURPOSE: To compare pure molecular diffusion, D, perfusion-related diffusion, D*, and perfusion fraction, f, determined from diffusion-weighted (DW) magnetic resonance (MR) imaging on the basis of the intravoxel incoherent motion (IVIM) theory in patients with type 2 diabetes with and without liver steatosis. MATERIALS AND METHODS: This prospective study was approved by the appropriate ethics committee, and written informed consent was obtained from all patients. Between December 2009 and September 2011, 108 patients with type 2 diabetes (51 men, 57 women; mean age, 50 years) underwent 3.0-T single-voxel point-resolved proton MR spectroscopy of the liver (segment VII…

MaleCirrhosisMagnetic Resonance SpectroscopyMESH : Fatty Liver[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingMESH : AgedMESH : Prospective Studies030218 nuclear medicine & medical imagingMESH: Linear Models0302 clinical medicineNuclear magnetic resonanceMESH: Aged 80 and overMESH : Diabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseMESH : Linear ModelsNonalcoholic fatty liver diseaseMESH : FemaleProspective StudiesMESH: Fatty LiverIntravoxel incoherent motion[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overMESH: AgedMESH: Statistics NonparametricMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingFatty liverMiddle AgedMESH : AdultMESH : Diffusion Magnetic Resonance Imaging3. Good health030220 oncology & carcinogenesisPotential confounderFemaleRadiologyMESH: Diabetes Mellitus Type 2Adultmedicine.medical_specialtyMESH : MaleMESH: Diffusion Magnetic Resonance ImagingStatistics Nonparametric03 medical and health sciencesmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingMESH : Middle AgedMESH : Aged 80 and overMESH : Statistics NonparametricAgedMESH: Humansbusiness.industryMESH: Magnetic Resonance SpectroscopyMESH : HumansMESH: Biological MarkersMESH: Adultmedicine.diseaseMr imagingMESH: MaleMESH: Prospective StudiesFatty LiverMESH : Biological MarkersDiffusion Magnetic Resonance ImagingDiabetes Mellitus Type 2Linear ModelsMESH : Magnetic Resonance SpectroscopySteatosisbusinessMESH: FemaleBiomarkersDiffusion MRI
researchProduct

POSTPRANDIAL HYPERGLYCEMIA IS A DETERMINANT OF PLATELET ACTIVATION IN EARLY 2 DIABETES MELLITUS

2010

BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early type 2 diabetes (baseline hemoglobin A(1c) < or = 7% and no previous hypoglycemic treatment) were randomly assigned to acarbose up to 100 mg three times a day or placebo, and evaluated every 4 weeks for 20 weeks. The main outcome measures were urinary 11-dehydro-thromboxane (TX)B(2) (marker of in vivo platelet activation) and 8-iso-prostaglandi…

Blood GlucoseMaleTime FactorsSettore MED/09 - Medicina InternaDinoprostpostprandial hyperglycemia; platelet activationMedicineEnzyme InhibitorsSettore MED/49 - Scienze Tecniche Dietetiche Applicatepostprandial hyperglycemiaAcarboseplateletHemoglobin AHematologyMiddle AgedPostprandial PeriodP-SelectinPostprandialTreatment OutcomeC-Reactive ProteinItalyFemaleBiological MarkersAcarboseType 2medicine.drugacarbose platelet activation postprandial hyperglycemia type 2 diabetes mellitusmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIAUrinary systemCD40 LigandGlycosylatedArginineExcretionBlood Glucose; Time Factors; Lipid Peroxidation; Middle Aged; Hemoglobin A Glycosylated; Postprandial Period; Diabetes Mellitus Type 2; Enzyme Inhibitors; Hypoglycemic Agents; P-Selectin; Platelet Activation; Aged; CD40 Ligand; Treatment Outcome; Male; Female; Thromboxane B2; Dinoprost; Italy; Arginine; Acarbose; Double-Blind Method; Humans; Biological Markers; Hyperglycemia; alpha-Glucosidases; C-Reactive ProteinDouble-Blind MethodInternal medicineDiabetes mellitusDiabetes MellitusHypoglycemic AgentsHumansGlycoside Hydrolase InhibitorsPlatelet activationGlycemicAgedGlycated Hemoglobinbusiness.industryType 2 Diabetes Mellitusalpha-Glucosidasesmedicine.diseasePlatelet ActivationThromboxane B2EndocrinologyDiabetes Mellitus Type 2HyperglycemiaLipid PeroxidationbusinessBiomarkers
researchProduct

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

2014

Importance There is an urgent need to identify reliable biomarkers of amyotrophic lateral sclerosis (ALS) progression for clinical practice and pharmacological trials. Objectives To correlate several hematological markers evaluated at diagnosis with ALS outcome in a population-based series of patients (discovery cohort) and replicate the findings in an independent validation cohort from an ALS tertiary center. Design, Setting, and Participants The discovery cohort included 712 patients with ALS from the Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis from January 1, 2007, to December 31, 2011. The validation cohort comprised 122 patients with ALS at different stages of…

MaleanalysisGastroenterologyCohort Studieschemistry.chemical_compoundAdult Aged Aged; 80 and over Amyotrophic Lateral Sclerosis; blood/mortality/pathology Biological Markers; blood Cohort Studies Creatinine; blood Disease Progression Female Humans Italy Lymphocyte Count Male Middle Aged Outcome Assessment (Health Care) Predictive Value of Tests Prognosis Sensitivity and Specificity Serum Albumin; analysisblood/mortality/pathologyOutcome Assessment Health Care80 and overAged 80 and overeducation.field_of_studybiologymedicine.diagnostic_testHazard ratioMiddle AgedPrognosisItalyErythrocyte sedimentation rateCreatinineCohortDisease ProgressionSettore MED/26 - NeurologiaBiological MarkersFemaleCohort studyAdultmedicine.medical_specialtyPopulationSerum albuminSensitivity and SpecificityOutcome Assessment (Health Care)bloodPredictive Value of TestsInternal medicinemedicineHumansLymphocyte CounteducationSerum AlbuminAgedCreatininebusiness.industryAmyotrophic Lateral SclerosisAlbuminchemistryImmunologybiology.proteinNeurology (clinical)ALSbusinessBiomarkersJAMA neurology
researchProduct

Non-invasive markers of airway inflammation and remodeling in childhood asthma

2009

To evaluate the relationship between pro-inflammatory and pro-remodeling mediators and severity and control of asthma in children, the levels of IL-8, MMP-9, TIMP-1 in induced sputum supernatants, the number of sputum eosinophils, as well as FeNO, were investigated in 35 asthmatic children, 12 with intermittent (IA) and 23 with moderate asthma (MA), and 9 controls (C). The patients with asthma were followed for 1 yr and sputum was obtained twice during the follow-up. Biomarker levels were correlated with the number of exacerbations. We found that IL-8, MMP-9, TIMP-1 and the numbers of eosinophils in induced sputum, as well as FeNO, were increased in children with IA and MA in comparison to …

MaleHumans; Disease Progression; Asthma; Child; Leukocyte Count; Eosinophils; Bronchitis; Follow-Up Studies; Sputum; Interleukin-8; Adolescent; Tissue Inhibitor of Metalloproteinase-1; Matrix Metalloproteinase 9; Biological Markers; Female; MaleAdolescentImmunologyInflammationDiseaseEosinophilBronchitiFollow-Up StudieLeukocyte CountImmunology and AllergyMedicineHumansNONINVASIVE MARKERS INFLAMMATION REMODELING CHILDHOOD ASTHMAProspective cohort studyBronchitisChildAsthmaChildhood asthmaTissue Inhibitor of Metalloproteinase-1business.industryInterleukin-8Airway inflammationSputumrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsMatrix Metalloproteinase 9Pediatrics Perinatology and Child HealthImmunologyBiological MarkerDisease ProgressionSputumBiomarker (medicine)Femalemedicine.symptombusinessBiomarkersHumanFollow-Up Studies
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct

Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic ir…

2014

Hepatitis C virus (HCV)-induced iron overload has been shown to promote liver fibrosis, steatosis, and hepatocellular carcinoma. The zonal-restricted histological distribution of pathological iron deposits has hampered the attempt to perform large-scale in vivo molecular investigations on the comorbidity between iron and HCV. Diagnostic and prognostic markers are not yet available to assess iron overload-induced liver fibrogenesis and progression in HCV infections. Here, by means of Spike-in SILAC proteomic approach, we first unveiled a specific membrane protein expression signature of HCV cell cultures in the presence of iron overload. Computational analysis of proteomic dataset highlighte…

Liver CirrhosisProteomicshepatitis C virusMaleMESH: Isotope LabelingHSCmedicine.disease_causeBiochemistry0302 clinical medicineFibrosisMESH: Up-RegulationMembrane Proteinhepatic stellate cellliver fibrosishepatic iron overload0303 health sciencesbiologyMESH: ProteomicsMedicine (all)hepatocellular carcinomaBiomedicine; hepatitis c infection; liver fibrosis; hepatic iron overload; vitronectinHepatitis C[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]Hepatitis CUp-Regulation3. Good healthcell culture-derived HCVIsotope Labeling030220 oncology & carcinogenesisHepatocellular carcinomaBiomedicine; Hepatic iron overload; Hepatitis C infection; Liver fibrosis; Vitronectin; Biomarkers; Cell Line; Hepatitis C; Humans; Iron Overload; Isotope Labeling; Liver Cirrhosis; Male; Membrane Proteins; Proteomics; Up-Regulation; Vitronectin; Molecular Biology; Biochemistry; Medicine (all)HCV[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyBiomarker (medicine)VitronectinMESH: Membrane ProteinsMESH: Liver CirrhosisHumanIron OverloadLiver CirrhosiHepatitis C virusvitronectinhepatitis c infectionCell LineMESH: Iron Overload03 medical and health sciencesmedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular Biology030304 developmental biologyMESH: Hepatitis CMESH: HumansMESH: Biological MarkersMembrane ProteinsLiver fibrosiProteomicBiomarkermedicine.diseaseMESH: VitronectinMESH: Maledigestive system diseasesMESH: Cell LineBiomedicineBiomedicine / Abbreviations: HCCHCVccImmunologyCancer researchHepatic stellate cellbiology.proteinSteatosisBiomarkersPROTEOMICS
researchProduct